Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Clinical Immunology (Orlando, Fla.)|July 20, 2016
Metastatic melanoma and immunotherapyBenjamin Herzberg, David E Fisher
The Oncologist|August 19, 2016
Immune Checkpoint Inhibitors in Non-Small Cell Lung CancerBenjamin Herzberg, Meghan J Campo, Justin F Gainor
The Oncologist|May 27, 2025
Thoracic SMARCA4-deficient undifferentiated tumor: diagnostic characteristics, molecular insights, and treatment approachesJunmin Song, Adam Gersten, Benjamin Herzberg, et al.
The Journal of Investigative Dermatology|April 18, 2014
Epidermal RelA specifically restricts contact allergen-induced inflammation and apoptosis in skinSnehlata Kumari, Benjamin Herzberg, Ruth Pofahl, et al.
The Oncologist|December 20, 2024
Weight loss in patients on osimertinib for metastatic EGFR-mutant non-small cell lung cancerLanyi Nora Chen, Xin Ma, Benjamin Herzberg, et al.
JCO Precision Oncology|June 29, 2023
Clinical and Genomic Features of Response and Toxicity to Sotorasib in a Real-World Cohort of Patients With Advanced <i>KRAS G12C</i>-Mutant Non-Small Cell Lung CancerRohit Thummalapalli, Ezra Bernstein, Benjamin Herzberg, et al.
The Oncologist|November 9, 2025
Phase Ib study of berzosertib, carboplatin, gemcitabine, and pembrolizumab in patients with squamous nonsmall lung cancer (ETCTN 10313)Liza C Villaruz, Benjamin Schluger, Hong Wang, et al.
The New England Journal of Medicine|May 6, 2026
Daraxonrasib in Previously Treated Advanced <i>RAS</i>-Mutated Pancreatic CancerBrian M Wolpin, Wungki Park, Ignacio Garrido-Laguna, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 24, 2025
Genomic and epigenomic ctDNA profiling in liquid biopsies from heavily pre-treated patients with DNA damage response-deficient tumorsIan M Silverman, Joseph D Schonoft, Benjamin Herzberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 8, 2024
A Multicenter Open-Label Randomized Phase II Study of Osimertinib With and Without Ramucirumab in Tyrosine Kinase Inhibitor-Naïve <i>EGFR</i>-Mutant Metastatic Non-Small Cell Lung Cancer (RAMOSE trial)Xiuning Le, Jyoti D Patel, Elaine Shum, et al.
Pageof 2